Comparative Pharmacology
Head-to-head clinical analysis: BREYNA versus TRI NORINYL 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREYNA versus TRI NORINYL 21 DAY.
BREYNA vs TRI-NORINYL 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREYNA is a contraceptive vaginal ring that releases ethinyl estradiol and etonogestrel. Etonogestrel is a progestogen that inhibits ovulation by suppressing gonadotropin release. Ethinyl estradiol enhances the contraceptive effect by stabilizing the endometrium and increasing cervical mucus viscosity.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects, increases viscosity of cervical mucus, alters endometrial morphology, and inhibits ovulation.
1 mg subcutaneously twice daily
One tablet (35 mcg ethinyl estradiol, 0.5 mg norethindrone for 7 days, 1 mg norethindrone for 9 days, 0.5 mg norethindrone for 5 days) orally once daily for 21 days, then 7 days off. Start on first day of menstrual period or first Sunday after onset.
None Documented
None Documented
Terminal elimination half-life is 12 hours; in patients with moderate to severe renal impairment, half-life may be prolonged up to 24 hours, requiring dose adjustment
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-23 hours. Steady-state reached within 5-7 days; clinical relevance for missed dose timing and resumption of ovulation.
Primarily renal excretion of unchanged drug (approximately 70%) and biliary/fecal elimination (approximately 30%)
Renal: ~50-60% (as metabolites); Fecal: ~30-40% (via bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive